Farmas USA

Si surte efecto, quizá podría irse al entorno de los 6.30, más sería demasiado.Yo le pondré un anzuelo ahí y otro sobre 6.10 por sí de desmadra.
Snta

je,je .... yo no las voy a dar cuartel, las largo directamente a la minima tonteria y punto.
ya las volvere a pillar

mañana se vera
SNTA

Por cierto, he entrado RENN ... TODO CHINOS, :))))

Renren.... Esa le gustaba a BeQuick y hace más de un año le hice un par de trades, pero la deje de seguir.Ha estado en máximos no hace mucho, no?

Mírate esta .
Será tarde para cortarla?
http://es.investing.com/equities/k-s-ag

no se yo ... esta muy cerca de minimos anuales ....

Por eso el ?
Pero si hace un rebote como hace un par de días, igual si le meto corto.
El sector (potasio) , están muuuuuy movido.

twit del bastardo, que siga asi:

"$VNDA must be raising money now to pay an extra-super-special bonus to its mystery regulatory consultant."

VNDA

Estos hijos de puta han separado la información en 3 documentos (anoche añadieron dos más) donde no constan fechas ni precio de venta al público y aún no los han presentado a la SEC. Igual por eso tampoco se ha acabado de notar. A ver qué pasa hoy cuando imagino que los presentarán en la SEC.

De entre los 3 documentos publicados y sesgados saco lo siguiente:

Registration of up to an additional 20% of securities for any offering registered on a S-3
The offering is subject to market conditions.

A la mitad el folleto de venta aparece esto otro:

We estimate that the net proceeds from the assumed sale of 4,000,000 shares of our common stock in this offering will be approximately $42.5 million, or approximately $49.0 million if the underwriters exercise in full their option to purchase additional shares of common stock, based on an assumed public offering price of $11.52 per share (the last reported sales price of our common stock on The NASDAQ Global Market on August 5, 2013), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

-> Ya sabemos quiénes las estaban aguantando anoche a ese precio tras la caída inicial. Esperemos que no se quede ahí.

We are authorized to issue 150,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.

-Según la información del Streetinsider eran 10 millones de acciones -> 34% de las acciones en circulación -> debería llevar a un precio de 7,5.

Ni lo uno ni lo otro supongo, pero ese gap en 8,50 digo yo que habría que cerrarlo.

Otra información relevante:

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Using this process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offering transactions up to a total dollar amount of $50,000,000.

From time to time, we may offer and sell shares of preferred stock, common stock, debt securities or warrants to purchase preferred stock, common stock or any combination of these securities, either separately or in units, in one or more offerings in amounts, at prices and on terms that we will determine at the time of the offering. The debt securities and warrants may be convertible into or exercisable or exchangeable for preferred stock, common stock or debt securities and the preferred stock may be convertible into or exchangeable for common stock.

A small number of institutional investors and private equity funds hold a significant number of shares of our common stock. Sales by these stockholders of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock.

The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013. As a result of achieving this regulatory milestone, we will incur certain costs in the third quarter of 2013 including a $3.0 million cash milestone obligation under our license agreement with Bristol-Meyers Squibb, a $0.5 million cash milestone obligation under a regulatory consulting agreement and additional non-cash stock-based compensation expense of $0.3 million for performancebased stock options and $0.2 million for performance-based restricted stock unit awards. In January 2013, we reported top-line results of the Phase IIb/III
clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of asimelteon as a monotherapy in the treatment of patients with MDD. The clinical study did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale (HAMD-17) after eight weeks of treatment as compared to placebo. As a result, all activities have been discontinued related to the MDD indication for tasimelteon.
We incurred $12.3 million in research and development costs for the six months ended June 30, 2013 directly attributable to our development of tasimelteon.

In December 2012, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum™ did not outweigh its risks and recommended against marketing authorization. We initiated an appeal of this opinion and requested a re-examination of the decision by the CHMP, but withdrew our Marketing Authorization Application in the first quarter of 2013 because the additional clinical data requested by the CHMP will not be available in the timeframe allowed by the EMA’s Centralized Procedure. We intend to reassess our European regulatory strategy for Fanaptum™ once the results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) being conducted by Novartis, become available. We incurred $0.3 million in research and development costs for the six months ended June 30, 2013 directly attributable to our development of Fanapt .
In the second half of 2013, we plan to initiate a proof of concept study for VLY-686 in treatment resistant pruritus in atopic dermatitis. We incurred $0.8 million in research and development costs for the six months ended June 30, 2013 directly attributable to our development of VLY-686.